ZA Biomedical Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A1
- Investors
-
3
ZA Biomedical General Information
Description
Manufacturer of innovative biopharmaceutical products intended for HPV-related diseases and various cancers. The company specailises in cancer therapeutic vaccines, topical peptide ointments for multidrug-resistant bacteria, treatments for genital warts and melanoma, and peptide-drug conjugates for advanced tumours, thereby improving patient outcomes in oncology and infectious disease care.
Contact Information
Website
www.wnlbiomed.comCorporate Office
- Room A, 5th Floor, East, Building A3
- Number 6 Shennong Road, Torch Development Zone
- Zhongshan, Guangdong 528400
- China
Corporate Office
- Room A, 5th Floor, East, Building A3
- Number 6 Shennong Road, Torch Development Zone
- Zhongshan, Guangdong 528400
- China
ZA Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A1) | 22-Sep-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 15-Sep-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Dec-2020 | $756K | $1.81M | Completed | Generating Revenue | |
| 1. Seed Round | 01-Nov-2019 | $1.06M | $1.06M | Completed | Startup |
ZA Biomedical Patents
ZA Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12702702-B2 | Application of caerin 1.1/1.9 combined with anti-cd47 antibody in preparing drug for treating melanoma | Active | 22-Nov-2022 | ||
| US-20250288656-A1 | Application of caerin 1.1/1.9 combined with anti-cd47 antibody in preparing drug for treating melanoma | Active | 22-Nov-2022 | ||
| WO-2024109339-A1 | Use of caerin1.1/1.9 combined with anti-cd47 antibody in preparation of drug for treatment of melanoma | Inactive | 22-Nov-2022 | ||
| AU-2017385913-A1 | Pharmaceutical composition comprising f1 and f3 polypeptides, and application thereof in treating hpv infection | Active | 27-Dec-2016 | ||
| AU-2017385913-B2 | Pharmaceutical composition comprising f1 and f3 polypeptides, and application thereof in treating hpv infection | Active | 27-Dec-2016 | A61K38/1703 |
ZA Biomedical Signals
ZA Biomedical Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| San Nuo Technology | Corporation | Minority | ||
| Zhongshan Torch Electronic Industry Fund Management | Venture Capital | Minority | ||
| Zhuhai Sanying Equity Investment Fund Management | Growth/Expansion | Minority |
ZA Biomedical FAQs
-
When was ZA Biomedical founded?
ZA Biomedical was founded in 2018.
-
Where is ZA Biomedical headquartered?
ZA Biomedical is headquartered in Zhongshan, China.
-
What is the size of ZA Biomedical?
ZA Biomedical has 5 total employees.
-
What industry is ZA Biomedical in?
ZA Biomedical’s primary industry is Drug Discovery.
-
Is ZA Biomedical a private or public company?
ZA Biomedical is a Private company.
-
What is ZA Biomedical’s current revenue?
The current revenue for ZA Biomedical is .
-
How much funding has ZA Biomedical raised over time?
ZA Biomedical has raised $1.81M.
-
Who are ZA Biomedical’s investors?
San Nuo Technology, Zhongshan Torch Electronic Industry Fund Management, and Zhuhai Sanying Equity Investment Fund Management have invested in ZA Biomedical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process